Neuros Medical Secures $56M for Altius FDA-Approved System
Deal News | Jul 09, 2025 | USVP Management Co LLC
Neuros Medical has recently secured a $56 million Series D funding round to advance the commercialization of its Altius Direct Electrical Nerve Stimulation System, a non-opioid treatment for chronic post-amputation pain that has received FDA approval. This successful funding round was led by EQT Life Sciences and featured contributions from current investors, including US Venture Partners, Amzak Health, among others. The Altius System serves as a groundbreaking solution addressing the chronic post-amputation pain affecting a significant portion of the amputee population in the U.S. Neuros Medical aims to utilize the funds to scale its commercial operations and expand the availability of this innovative treatment, offering a patient-controlled system that inhibits pain transmission from damaged peripheral nerves to the central nervous system. The CEO of Neuros Medical and representatives from EQT Life Sciences have expressed their commitment to addressing this urgent medical need and improving the quality of life for millions of amputees.
Sectors
- Healthcare
- Medical Devices
- Venture Capital
Geography
- United States – Neuros Medical is based in the U.S., and the funding is intended to support U.S. commercialization of the Altius System.
- Sweden – EQT Life Sciences, which led the funding round, is an international investment firm based in Sweden.
Industry
- Healthcare – The article discusses Neuros Medical's development and upcoming commercialization of a healthcare innovation, the Altius System, which addresses chronic post-amputation pain.
- Medical Devices – Neuros Medical's Altius System is a medical device designed for nerve stimulation, targeting chronic pain management for amputees.
- Venture Capital – The article involves companies such as USVP and EQT Life Sciences, which are venture capital firms participating in the investment round.
Financials
- $56 million – Series D funding secured by Neuros Medical for the commercialization of its Altius System.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Neuros Medical, Inc. | Target | Company | Neuros Medical is the maker of the Altius System and focuses on non-opioid pain treatments for chronic post-amputation pain. |
| USVP Management Co LLC | Investor | Company | US Venture Partners participated in the Series D funding round for Neuros Medical. |
| EQT Life Sciences | Lead Investor | Company | EQT Life Sciences led the $56 million Series D funding round for Neuros Medical. |
| Amzak Health | Investor | Company | Amzak Health is one of the existing investors participating in the Series D round for Neuros Medical. |
| David Veino | CEO | Person | David Veino is the President and CEO of Neuros Medical, leading the company's efforts to commercialize the Altius System. |
| Fouad Azzam, Ph.D. | Partner | Person | Fouad Azzam is a Partner in the EQT Life Sciences advisory team, supporting Neuros Medical's growth and commercialization strategy. |